ATE200626T1 - Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats - Google Patents

Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats

Info

Publication number
ATE200626T1
ATE200626T1 AT95926057T AT95926057T ATE200626T1 AT E200626 T1 ATE200626 T1 AT E200626T1 AT 95926057 T AT95926057 T AT 95926057T AT 95926057 T AT95926057 T AT 95926057T AT E200626 T1 ATE200626 T1 AT E200626T1
Authority
AT
Austria
Prior art keywords
conjugate
peptide
targeting compound
modified superantigen
modified
Prior art date
Application number
AT95926057T
Other languages
English (en)
Inventor
Lars Abrahmsen
Per Bjoerk
Mikael Dohlsten
Terje Kalland
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE200626T1 publication Critical patent/ATE200626T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95926057T 1994-07-11 1995-06-07 Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats ATE200626T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402430A SE9402430L (sv) 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
PCT/SE1995/000681 WO1996001650A1 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate

Publications (1)

Publication Number Publication Date
ATE200626T1 true ATE200626T1 (de) 2001-05-15

Family

ID=20394684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926057T ATE200626T1 (de) 1994-07-11 1995-06-07 Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats

Country Status (26)

Country Link
US (3) US7226601B1 (de)
EP (1) EP0766566B1 (de)
JP (1) JP4175489B2 (de)
KR (1) KR100377506B1 (de)
CN (1) CN1089606C (de)
AT (1) ATE200626T1 (de)
AU (1) AU699147B2 (de)
CA (1) CA2194673C (de)
DE (1) DE69520739T2 (de)
DK (1) DK0766566T3 (de)
ES (1) ES2158950T3 (de)
FI (1) FI118150B (de)
GR (1) GR3036187T3 (de)
HU (1) HU221254B1 (de)
IL (1) IL114445A (de)
MY (1) MY112916A (de)
NO (1) NO320151B1 (de)
NZ (1) NZ289951A (de)
PL (1) PL180747B1 (de)
PT (1) PT766566E (de)
RU (1) RU2183215C2 (de)
SE (1) SE9402430L (de)
TW (1) TW413636B (de)
UA (1) UA73067C2 (de)
WO (1) WO1996001650A1 (de)
ZA (1) ZA955746B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BR9815493A (pt) * 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
DE19827837A1 (de) * 1998-06-23 1999-12-30 Ernst Gleichmann Universell an Haupthistokompatibilitätskomplexmoleküle der Klasse II bindende Peptide zur prädiktiven Testung, Diagnostik, Prophylaxe und Therapie von Sensibilisierungen gegen Chemikalen
US7491402B2 (en) 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
NZ519371A (en) 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1812574A2 (de) * 2004-11-18 2007-08-01 Avidex Limited Lösliche bifunktionelle proteine
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
WO2014025199A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
KR20250071286A (ko) 2016-01-10 2025-05-21 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
WO2020013803A1 (en) * 2018-07-09 2020-01-16 Synthis, Llc Antibody-alk5 inhibitor conjugates and their uses
CA3139899A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627644A (en) 1968-03-01 1971-12-14 Hajime Okamoto Process for the cultivation of hemolytic streptococci
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4268434A (en) 1979-01-09 1981-05-19 Higerd Thomas B Immunosuppressive extracellular product from oral bacteria
SU1304736A3 (ru) * 1981-04-14 1987-04-15 Др.Мадаус Унд Ко (Фирма) Способ получени противоопухолевого средства
US5091091A (en) 1981-11-06 1992-02-25 Terman David S Protein A perfusion and post perfusion drug infusion
US4699783A (en) 1983-03-11 1987-10-13 Terman David S Products and methods for treatment of cancer
US4681870A (en) 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
IT1192014B (it) 1986-06-27 1988-03-31 Rubinetterie Mariani Spa Becco di erogazione per lavabo o simile apparecchio idraulico con comando del salterello
US4980160A (en) 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
EP0355047B1 (de) 1988-07-22 1993-06-30 Imre Corporation Gereinigte Protein A-Zusammensetzungen und Verfahren zu ihrer Herstellung
SE8903100D0 (sv) 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
EP1129717B2 (de) 1990-01-17 2013-03-06 TERMAN, David S. Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
US6197299B1 (en) * 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
DE69122777T2 (de) * 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
JPH08500328A (ja) 1992-01-28 1996-01-16 ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン 突然変異したスーパー抗原の保護作用
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy

Also Published As

Publication number Publication date
AU699147B2 (en) 1998-11-26
EP0766566A1 (de) 1997-04-09
CA2194673C (en) 2009-08-04
MY112916A (en) 2001-10-31
RU2183215C2 (ru) 2002-06-10
UA73067C2 (en) 2005-06-15
IL114445A (en) 1999-09-22
FI970100A0 (fi) 1997-01-10
HUT77257A (hu) 1998-03-02
AU2994095A (en) 1996-02-09
PL318162A1 (en) 1997-05-26
WO1996001650A1 (en) 1996-01-25
JP4175489B2 (ja) 2008-11-05
IL114445A0 (en) 1995-11-27
NO970108L (no) 1997-02-20
ZA955746B (en) 1996-02-20
DE69520739T2 (de) 2001-09-20
EP0766566B1 (de) 2001-04-18
US20060062795A1 (en) 2006-03-23
HU221254B1 (en) 2002-09-28
US7226601B1 (en) 2007-06-05
US20050260215A1 (en) 2005-11-24
CN1152877A (zh) 1997-06-25
PL180747B1 (pl) 2001-04-30
ES2158950T3 (es) 2001-09-16
GR3036187T3 (en) 2001-10-31
NO970108D0 (no) 1997-01-10
FI970100L (fi) 1997-01-10
SE9402430L (sv) 1996-01-12
DE69520739D1 (de) 2001-05-23
JPH11500407A (ja) 1999-01-12
CA2194673A1 (en) 1996-01-25
NO320151B1 (no) 2005-10-31
PT766566E (pt) 2001-09-28
KR100377506B1 (ko) 2003-06-11
SE9402430D0 (sv) 1994-07-11
NZ289951A (en) 1998-12-23
CN1089606C (zh) 2002-08-28
DK0766566T3 (da) 2001-08-13
FI118150B (fi) 2007-07-31
TW413636B (en) 2000-12-01
HK1012226A1 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
ATE200626T1 (de) Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
ATE267610T1 (de) Glykosylierte igg antikörper
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
Galloway et al. Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DE69834808D1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
EP0820469A4 (de) Identifikation, reinigung und verwendungen von leczymen und karbohydratliganden
Rousseaux et al. Rat IgG subclasses: differences in affinity to protein A-Sepharose
ATE174967T1 (de) Monoklonale antikörper gegen glykoprotein p
Lees et al. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody.
GEP20063774B (en) Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
US4902495A (en) IgE Fc directed delivery system
BR9101117A (pt) Produto que compreende um ou mais veiculos de material enzimatico e processo para distribuir um agente ativo a um sitio
Komisar et al. Localization of binding sites of staphylococcal enterotoxin B (SEB), a superantigen, for HLA-DR by inhibition with synthetic peptides of SEB
Raison et al. Conformation dependence of a monoclonal antibody defined epitope on free human kappa chains
ATE122895T1 (de) Monoklonale antikörper gegen den interleukin 2- rezeptor.
Léonetti et al. Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins
Laky et al. Binding and cytotoxic effect of ricin toxin on multivalent hybrid antibody-coated target cells
RU2020137888A (ru) Человеческие антитела, связывающиеся с ror2
TH42174A3 (th) แอนติบอดีที่ทำให้เหมือนมนุษย์ซึ่งจำเพาะสำหรับ 4-1bb ของมนุษย์และสารผสมทางเภสัชกรรม ซึ่งประกอบด้วยสิ่งเดียวกัน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner